Diabetes Tech: A randomized CONNECT trial at ADA 2026 found Dexcom G7 CGM cut A1C by 1.6% over 26 weeks in adults with type 2 diabetes not using insulin, with results strong enough to support broader primary-care use. Obesity/GLP-1 Pipeline: Phase 3 data at ADA 2026 showed retatrutide delivering substantial weight loss and A1C improvements in both type 2 diabetes and obesity/overweight groups. Regulation & Access: Telangana’s Drugs Control Administration inspected 166 medical shops tied to online pharmacies and issued show-cause notices to 41 over issues like missing bills, weak prescription record-keeping, and dispensing without valid prescriptions. Aging & Care Delivery: Qatar launched “Ahlan Oral Health 2026” to boost oral health for older adults via community and home visits plus training for caregivers and healthcare staff. Long-Term Care Watch: CMS Q1 2026 ownership and star ratings highlighted wide variation across U.S. nursing homes, with some facilities scoring 5 stars while others sat at 1, alongside reported fines and penalties. Wellness Industry: The Retreat Costa Rica debuted its Vida Mía Longevity Centre with physician-guided nervous system and “cellular regeneration” programming. Clinical Research Buzz: An AI-designed universal coronavirus vaccine completed its first human trial with a reported 100% safety profile and multi-strain immune response.